5月6日 - ** 在美国 FDA 任命 (link) Vinay Prasad 担任其生物制品评估与研究中心主任(CBER 之后，疫苗制造商 莫德纳 MRNA.O 和基因疗法开发商的股价下跌了 12% 至 22)
** 普拉萨德是 COVID-19 疫苗和面罩任务的激烈批评者
** 作为 CBER 主任，普拉萨德将负责疫苗和基因疗法的监管工作
** 莫德纳股价下跌12.4%，NovavaxNVAX.O下跌5.2%，而辉瑞PFE.N此前在宣布 (link) 药品成本后下跌，其跌幅扩大至3%。
** Sarepta Therapeutics SRPT.O等基因治疗开发商股价下跌21.5%，Taysha Gene Therapies TSHA.O下跌20.7%，Capricor Therapeutics CAPR.O下跌20.3%。
** 在美国上市的 CRISPR Therapeutics CRSP.BN 下跌 9.6%，Solid Biosciences SLDB.O 下跌 15.3%、
** MRNA 下跌 41.3%，SRPT 下跌 61.1
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.